These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 17353651

  • 1. Left ventricular (LV) geometry and dipping state are determinants of LV mass reduction with angiotensin-converting enzyme inhibitor antihypertensive treatment.
    Aznaouridis KA, Vyssoulis GP, Karpanou EA, Marinakis AG, Barbetseas JD, Zervoudaki AI, Cokkinos DV, Stefanadis CI.
    Blood Press Monit; 2007 Apr; 12(2):87-94. PubMed ID: 17353651
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V, Devereux RB.
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [Abstract] [Full Text] [Related]

  • 3. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
    He H, Li LM, Cao WH, Sun NL, Liu MZ, Hu YH.
    Ann Hum Biol; 2005 Jun; 32(1):30-43. PubMed ID: 15788353
    [Abstract] [Full Text] [Related]

  • 4. Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy.
    Gosse P, Roudaut R, Herrero G, Dallocchio M.
    J Cardiovasc Pharmacol; 1990 Jun; 16 Suppl 5():S145-50. PubMed ID: 11527119
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H, Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, Takane H.
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [Abstract] [Full Text] [Related]

  • 6. Insulin-like growth factor-1 and cardiac mass in essential hypertension: comparative effects of captopril, lisinopril and quinapril.
    Díez J, Laviades C.
    J Hypertens Suppl; 1994 Jul; 12(4):S31-6. PubMed ID: 7965272
    [Abstract] [Full Text] [Related]

  • 7. [Effect of cilazapril therapy on diastolic filling and left ventricular hypertrophy in patients with arterial hypertension].
    De Simone R, Irace L, Perna B, Caruso C, Guida M, Iacono A.
    Minerva Cardioangiol; 1993 May; 41(5):205-9. PubMed ID: 8355860
    [Abstract] [Full Text] [Related]

  • 8. Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan.
    Avanza AC, El Aouar LM, Mill JG.
    Arq Bras Cardiol; 2000 Feb; 74(2):103-17. PubMed ID: 10904284
    [Abstract] [Full Text] [Related]

  • 9. Reverse white-coat effect as an independent risk for left ventricular concentric hypertrophy in patients with treated essential hypertension.
    Tomiyama M, Horio T, Kamide K, Nakamura S, Yoshihara F, Nakata H, Nakahama H, Kawano Y.
    J Hum Hypertens; 2007 Mar; 21(3):212-9. PubMed ID: 17167525
    [Abstract] [Full Text] [Related]

  • 10. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor.
    Kohno M, Horio T, Yokokawa K, Yasunari K, Ikeda M, Minami M, Kurihara N, Takeda T.
    Am J Med; 1995 Mar; 98(3):257-65. PubMed ID: 7872342
    [Abstract] [Full Text] [Related]

  • 11. Changes in plasma cardiac natriuretic peptides concentrations during 1 year treatment with angiotensin-converting enzyme inhibitor in elderly hypertensive patients with left ventricular hypertrophy.
    Kohno M, Yokokawa K, Yasunari K, Kano H, Minami M, Hanehira T, Yoshikawa J.
    Int J Clin Pharmacol Ther; 1997 Jan; 35(1):38-42. PubMed ID: 9021441
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin-converting enzyme inhibitors influence left ventricular mass and function independently of the antihypertensive effect.
    Grandi AM, Laurita E, Solbiati F, Marchesi C, Maresca AM, Nicolini E, Guasti L, Venco A.
    J Cardiovasc Pharmacol; 2006 Nov; 48(5):207-11. PubMed ID: 17110802
    [Abstract] [Full Text] [Related]

  • 13. Effects of angiotensin-converting enzyme gene polymorphism and serum vitamin D levels on ambulatory blood pressure measurement and left ventricular mass in Turkish hypertensive population.
    Kulah E, Dursun A, Aktunc E, Acikgoz S, Aydin M, Can M, Dursun A.
    Blood Press Monit; 2007 Aug; 12(4):207-13. PubMed ID: 17625392
    [Abstract] [Full Text] [Related]

  • 14. [I/D gene polymorphism of the angiotensin-converting enzyme and left ventricular hypertrophy. Response to converting enzyme inhibitors].
    Rugale C, du Cailar G, Ribstein J, Mimran A.
    Arch Mal Coeur Vaiss; 2003 Aug; 96(7-8):772-5. PubMed ID: 12945221
    [Abstract] [Full Text] [Related]

  • 15. Improvement of diastolic function after regression of left ventricular hypertrophy.
    Teniente-Valente R, Solorio S, Vargas-Salado E, Aguirre-Vázquez C, Hernández-González MA, Olvera-Lopez JA, Rodríguez-Mariscal L, Luna-Ruiz MA, Guillén Contreras JM, Murillo Ortiz BO.
    Arch Cardiol Mex; 2008 Aug; 78(4):392-9. PubMed ID: 19205547
    [Abstract] [Full Text] [Related]

  • 16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 17. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E, Muiesan ML.
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [Abstract] [Full Text] [Related]

  • 18. [Association between angiotensin converting enzyme gene, chymase gene and regression of left ventricular hypertrophy in patients treated with angiotensin converting enzyme inhibitors].
    He H, Li LM, Cao WH, Liu MZ, Sun NL, Lü J, Hu YH.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Sep; 25(9):756-60. PubMed ID: 15555355
    [Abstract] [Full Text] [Related]

  • 19. Different role of wave reflection magnitude and timing on left ventricular mass reduction during antihypertensive treatment.
    Hashimoto J, Westerhof BE, Westerhof N, Imai Y, O'Rourke MF.
    J Hypertens; 2008 May; 26(5):1017-24. PubMed ID: 18398345
    [Abstract] [Full Text] [Related]

  • 20. Twenty-four-hour heart rate and blood pressure are additive markers of left ventricular mass in hypertensive subjects.
    Zakopoulos NA, Ikonomidis I, Vemmos KN, Manios E, Spiliopoulou I, Tsivgoulis G, Spengos K, Psaltopoulou D, Mavrikakis M, Moulopoulos SD.
    Am J Hypertens; 2006 Feb; 19(2):170-7. PubMed ID: 16448887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.